ClinicalTrials.gg
RecruitingNCT07432594Updated Nov 4, 2026

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

A Phase 2 interventional study of Aitua Combination Antibody and Albumin-Bound Paclitaxel /nab-Paclitaxel in High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers and Primary Peritoneal Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 4, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Fallopian Tube Neoplasms with a site in China — 33 open to participants now, 40 under way, 17 of them phase 3. Fallopian Tube Neoplasms · China.

Planned enrollment
41st of 59
82 · median 220
Started
2026
with 11 others
Phase 2
20 of 59
13 open now
Primary completion
2027-05
later than 15 of 39 live
Registered
47th of 59
by date

Among the 59 studies in Fallopian Tube Neoplasms with a site in China, this one is the 41st largest by planned enrollment, is one of 12 that started in 2026, is one of 20 in phase 2, reaches primary completion later than 15 of the 39 other live ones, and was the 47th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

33 of the 59 studies in Fallopian Tube Neoplasms with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Fallopian Tube Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for patients with advanced high-grade serous ovarian cancer.

The study focuses on patients who are newly diagnosed with Stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer and are assessed as unable to achieve satisfactory tumor debulking (R0 resection) initially.

Participants will be randomized in a 1:1 ratio into two groups:

Experimental Group: Receives Nab-paclitaxel and Carboplatin combined with Aitua Combination Antibody.

Control Group: Receives Nab-paclitaxel and Carboplatin alone.

Both groups will receive 3 cycles of neoadjuvant treatment followed by Interval Debulking Surgery (IDS). The primary goal is to compare the R0 resection rate (complete removal of macroscopic tumor) between the two groups during surgery. Secondary goals include assessing pathological complete response (pCR), objective response rate, progression-free survival, and safety. The study also aims to explore how this combination therapy affects the tumor immune microenvironment.

Read the detailed description

Background and Rationale: Ovarian cancer has the highest mortality rate among gynecological malignancies, with High-Grade Serous Carcinoma (HGSC) being the most common subtype. HGSC is characterized by a highly immunosuppressive Tumor Immune Microenvironment (TiME), often referred to as an "immune desert," which limits the efficacy of single-agent immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway.

Investigational Agent: Aitua Combination Antibody (QL1706) is a novel bifunctional antibody targeting both PD-1 and CTLA-4. Dual blockade of these pathways may synergistically activate anti-tumor immune responses: CTLA-4 inhibition promotes early T-cell activation in lymph nodes, while PD-1 inhibition reverses T-cell exhaustion within the tumor microenvironment. Previous studies in cervical cancer have shown that this bispecific antibody may offer improved efficacy with a manageable toxicity profile compared to combining two separate antibodies.

Chemotherapy Synergy: Albumin-bound paclitaxel (Nab-paclitaxel), a standard component of ovarian cancer treatment, avoids the need for corticosteroid pretreatment and has been shown to potentially enhance immune cell infiltration and regulate macrophage polarization. This study hypothesizes that combining Nab-paclitaxel/Carboplatin with the PD-1/CTLA-4 bispecific antibody will remodel the immune microenvironment and improve surgical outcomes.

Study Design: This is a single-center, open-label (with blinded assessment), randomized Phase II trial. Approximately 82 eligible patients will be stratified by FIGO stage (IIIC vs. IV) and randomized 1:1 to the experimental or control arm.

Neoadjuvant Phase: Patients receive 3 cycles of therapy (Q3W).

Surgical Phase: Patients with responsive or stable disease will undergo Interval Debulking Surgery (IDS). The primary endpoint is the R0 resection rate (no macroscopic residual disease).

Adjuvant Phase: Post-surgery, patients will continue treatment with the assigned regimen for additional cycles.

Translational Research: Tumor tissue, ascites, and peripheral blood will be collected at baseline, pre-surgery, and during therapy to analyze changes in immune cell subsets (e.g., via scRNA-seq, mIHC/mIF) and identify potential predictive biomarkers.

03

Conditions studied

  • High-grade Serous Ovarian Cancer (HGSOC)
  • Fallopian Tube Cancers
  • Primary Peritoneal Cancer

Keywords

  • Neoadjuvant Chemotherapy
  • Interval Debulking Surgery
  • PD-1/CTLA-4 Bispecific Antibody
  • Aitua Combination Antibody
  • Nab-paclitaxel
  • Carboplatin
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • confirmed high-grade serous ovarian cancer (HGSC), fallopian tube cancer, or primary peritoneal cancer.
  • International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV.
  • (ECOG) performance status of 0-1.
  • Assessed by a multidisciplinary team (MDT) based on imaging (± laparoscopic exploration) as initially unable to achieve satisfactory tumor debulking (R0 resection).
  • At least one according to (RECIST) version 1.1 criteria.
  • Major organ function is basically normal.
  • Willing to provide tumor tissue, peripheral blood, and ascites samples for translational research.

Exclusion criteria

Exclusion Criteria:

  • Pathological types other than high-grade serous carcinoma (HGSC).
  • Prior receipt of any form of anti-tumor therapy.
  • History of disease or requiring therapy.
  • Known allergy to study drug components.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Nab-Paclitaxel + Carboplatin + Aitua Combo Ab

    Participants receive Nab-paclitaxel (260 mg/m\^2), Carboplatin (AUC 4-5), and Aitua Combination Antibody (5 mg/kg) intravenously on Day 1 of each 3-week cycle for 3 cycles as neoadjuvant therapy, followed by Interval Debulking Surgery (IDS).

    Drug: Aitua Combination Antibody · Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel · Drug: Carboplatin (AUC 5) · Procedure: Interval Debulking Surgery

  • Active comparator
    Nab-Paclitaxel + Carboplatin

    Participants receive Nab-paclitaxel (260 mg/m\^2) and Carboplatin (AUC 4-5) intravenously on Day 1 of each 3-week cycle for 3 cycles as neoadjuvant therapy, followed by Interval Debulking Surgery (IDS).

    Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel · Drug: Carboplatin (AUC 5) · Procedure: Interval Debulking Surgery

Interventions

  • DrugAitua Combination Antibody

    Drug page: Iparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered via intravenous infusion at a dose of 5 mg/kg on Day 1 of each 3-week cycle.

    Also known as: PD-1/CTLA-4 Bispecific Antibody, QL1706

  • DrugAlbumin-Bound Paclitaxel /nab-Paclitaxel

    Drug page: Albumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered via intravenous infusion at a dose of 260 mg/m\^2 on Day 1 of each 3-week cycle.

  • DrugCarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered via intravenous infusion at a dose of AUC 5 on Day 1 of each 3-week cycle.

  • ProcedureInterval Debulking Surgery

    Performed after 3 cycles of neoadjuvant therapy. The goal is to achieve R0 resection (no macroscopic residual disease).

06

What researchers measure

Primary outcomes

  1. Rate of R0 resection

    Defined as the percentage of participants achieving optimal debulking surgery with no macroscopic residual disease (R0) after neoadjuvant therapy. This is assessed by the surgeon at the time of interval debulking surgery (IDS).

    Time frame: At the time of surgery, up to 12 weeks

Secondary outcomes

  1. Pathological complete response (pCR) rate

    Defined as the proportion of participants with no evidence of invasive cancer in the surgical specimens collected during interval debulking surgery (IDS).

    Time frame: At the time of surgery, up to 12 weeks

  2. Objective response rate (ORR)

    Defined as the percentage of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, based on independent radiological review.

    Time frame: From baseline up to approximately 2 years

  3. Disease control rate (DCR)

    Defined as the percentage of participants who achieve a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From baseline up to approximately 2 years

  4. Progression-free survival (PFS)

    Defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause, whichever occurs first.

    Time frame: From randomization up to approximately 2 years

  5. Incidence and severity of adverse events (AEs)

    Safety will be assessed by monitoring the frequency and severity of adverse events (AEs) and serious adverse events (SAEs), graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. This includes monitoring for immune-related adverse events (irAEs).

    Time frame: Through 28 days after the last dose of study drug, up to approximately 2 years

  6. Change from baseline in EORTC QLQ-C30 quality-of-life scores

    Patient-reported health-related quality of life will be assessed using the 30-item European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Global health status/quality of life, functioning, and symptom scores will be calculated separately and transformed to a 0-100 scale according to the EORTC scoring manual. Higher global health status/quality of life and functioning scores indicate better outcomes, whereas higher symptom and financial difficulty scores indicate worse outcomes. Change from baseline will be assessed at each scheduled post-baseline visit.

    Time frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).

  7. Change from baseline in EORTC QLQ-OV28 domain scores

    Patient-reported ovarian cancer-specific quality of life will be assessed using the 28-item European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Cancer Module (EORTC QLQ-OV28). The questionnaire assesses abdominal/gastrointestinal symptoms, peripheral neuropathy, other chemotherapy side effects, hormonal/menopausal symptoms, body image, attitude to disease/treatment, and sexual functioning. Domain scores will be calculated separately and transformed to a 0-100 scale. Higher symptom/problem scores indicate worse outcomes; sexual functioning scores will be oriented so that higher scores indicate better functioning. Change from baseline will be assessed at each scheduled post-baseline visit.

    Time frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).

Other outcomes

  1. Change in tumor immune microenvironment (TiME) characteristics

    Exploratory analysis of immune cell subsets, such as cluster of differentiation 8 positive (CD8+) T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), in tumor tissue and peripheral blood. This uses single-cell RNA sequencing (scRNA-seq), multiplex immunohistochemistry/immunofluorescence (mIHC/mIF), and flow cytometry to evaluate the immunomodulatory effects of the treatment.

    Time frame: At baseline, and at the time of surgery (up to 12 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to institutional privacy regulations and patient confidentiality, individual participant data (IPD) will not be shared publicly.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.

Of 98 non-industry phase 2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 10 months is below that.

Counting every sponsor, half of 125 studies reached it within 56 months; a quarter within 42 and three quarters within 90.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Jul 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 25, 2026
StartActual
Jul 23, 2026was Mar 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
1 site added — first site in China
Show site
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
Nov 4, 2026
Start date
Mar 1, 2026→Jul 23, 2026 (actual)
Nov 4, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedChange from baseline in EORTC QLQ-C30 quality-of-life scoresTime frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).
  • AddedChange from baseline in EORTC QLQ-OV28 domain scoresTime frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
    Start date Mar 1, 2026→Jul 23, 2026 (now actual)
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedChange from baseline in EORTC QLQ-C30 quality-of-life scoresTime frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).
    • AddedChange from baseline in EORTC QLQ-OV28 domain scoresTime frame: Baseline (before dosing on Cycle 1 Day 1), before dosing on Day 1 of Cycles 2 and 3, and within 7 days before interval debulking surgery (up to approximately 12 weeks).
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07432594
Responsible party
NING LI-GYN (Chief Physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Feb 25, 2026
Start date
Jul 23, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Ning Li, MD
Contact
liningnci@126.com
8610-87787211
Ning Li, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iparomlimab/Tuvonralimab

Start the discussion